Mobile

A study to evaluate the long-term safety of adalimumab in subjects with non-infectious intermediate-, posterior-, or pan-uveitis who participated in Study M10-877 or Study M10-880

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016196-29

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the long-term safety of adalimumab 40 mg given every other week (eow) subcutaneously (SC) in subjects with non-infectious intermediate-, posterior-, or pan-uveitis who participated in Study M10-877 or Study M10-880. Long-term efficacy will also be assessed.

Critère d'inclusion

  • Non-infectious Intermediate, Posterior, or Pan- Uveitis

Liens